Navigation Links
Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Evaluating Picoplatin in Small Cell Lung Cancer Reaches 320th Event Target
Date:9/15/2009

SOUTH SAN FRANCISCO, Calif., Sept. 15 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) today announced that 320 evaluable events (patient deaths) have occurred in its pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial, which is being conducted in accordance with a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA), evaluating picoplatin in the treatment of small cell lung cancer (SCLC).

"The 320th event in our pivotal registration SPEAR trial was defined in our SPA with the FDA to enable the Company to begin final analysis of data. Our goal is to complete and report the results of our preliminary analysis in the fourth quarter of 2009 and, if positive, initiate the rolling New Drug Application filing process for picoplatin by year-end under the Fast Track designation previously granted by the FDA," said Jerry McMahon, Ph.D., chairman and CEO of Poniard. "The SPA helps ensure that the design and clinical endpoints of our randomized trial and our planned analysis of the study are aligned with the FDA to support submission of an NDA."

SPEAR Trial Design

The international, multi-center, randomized, controlled Phase 3 SPEAR trial is evaluating the efficacy and safety of picoplatin as second-line therapy in 401 cancer patients with SCLC who have not responded to or who relapsed following first-line platinum-based therapy. The primary endpoint of the trial is overall survival. The Statistical Analysis Plan of the trial, as agreed to in the SPA, is 90 percent powered to show a 33 percent reduction in risk in overall survival for picoplatin treatment with best supportive care (BSC) compared with BSC alone (hazard ratio of 0.67; p<0.05). The trial completed enrollment
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... - Following the announcement on April 30, 2009, of ... Bionics Inc. ("Victhom", TSX: VHB) and Otto Bock HealthCare ... the transaction contemplated by the partnership agreement and the ... concurrent restructuring of its outstanding convertible debentures by way ...
... Fortune Magazine has named Neogen Corporation (Nasdaq: NEOG ... best stocks to retire on." , , Fortune ... to assemble a diversified, dependable portfolio of stocks for the long ... but also hold steady during darker times." , , ...
... Investors in a Financial Crisis, Draws Regional Biopharmaceutical Executives, ... 18 Biotech companies throughout the country are reeling ... 370 small-cap funds slated to run out of cash ... concluded during a life sciences symposium presented by ...
Cached Biology Technology:Victhom announces completion of joint venture agreement with Otto Bock for Neurobionix activities 2Victhom announces completion of joint venture agreement with Otto Bock for Neurobionix activities 3Victhom announces completion of joint venture agreement with Otto Bock for Neurobionix activities 4Neogen Named to Fortune's List of 40 Stocks 'To Retire On' 2Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 2Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 3Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 4Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 5
(Date:4/16/2014)... of a leaf looks like one seamless surface; however, ... of a patchwork of cells in a variety of ... take on their own unique forms, Caltech biologist Elliot ... pinpoint the shape-controlling factors in pavement cells, which are ... plants. They found that these unusual shapes were the ...
(Date:4/16/2014)... "brush border" a densely packed array of ... of the cells that line our intestines., Vanderbilt ... build this specialized structure, which is critical for ... published April 10 in the journal Cell ... brush border assembly and increase our understanding of ...
(Date:4/16/2014)... Geologic and soil processes are to blame for significant ... to a study published recently in the Journal ... soil samples from all corners of Ohio showed that ... level of concern recommended by the U.S. Environmental Protection ... the authors, who note that regulatory levels typically are ...
Breaking Biology News(10 mins):For cells, internal stress leads to unique shapes 2Vanderbilt researchers discover how intestinal cells build nutrient-absorbing surface 2Vanderbilt researchers discover how intestinal cells build nutrient-absorbing surface 3Significant baseline levels of arsenic found in Ohio soils are due to natural processes 2Significant baseline levels of arsenic found in Ohio soils are due to natural processes 3Significant baseline levels of arsenic found in Ohio soils are due to natural processes 4
... its workshop on ,Update on pluripotent stem cells (hESC and ... culture of pluripotent stem cells,. The objective of the course ... on the state of the art of pluripotent stem cells. ... days 9-12 February is to provide the participants with the ...
... has launched Illuminea, a new quarterly newsletter for academic ... up-to-date with the latest developments at OUP and across ... for Journals at OUP, and member of the Editorial ... library community we have developed a strong and broad ...
... levels of DNA damage have for the first time been ... the inherited, progressive nervous system disease called Friedreich,s ataxia (FRDA), ... the University of Pittsburgh Cancer Institute (UPCI). The findings, ... the molecular abnormalities that lead to the disease, as well ...
Cached Biology News:Update on pluripotent stem cells (hESC and iPS) 2Excess DNA damage found in cells of patients with Friedreich's ataxia 2
... output accessory lessens the expensive task ... laboratories with multiple mass spectrometers. It ... from Agilent 1100 Series LC/MSD quadrupole ... transmits the analog data directly to ...
... SOS Protein Solubility Service, We deliversoluble ... New SOS technology yields the best soluble ... applied on each clone submitted , Powerful ... ,The new protein Solubility Optimization Service (SOS) ...
... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
Biology Products: